1142224-43-8Relevant articles and documents
Discovery of AM-1638: A potent and orally bioavailable GPR40/FFA1 full agonist
Brown, Sean P.,Dransfield, Paul J.,Vimolratana, Marc,Jiao, Xianyun,Zhu, Liusheng,Pattaropong, Vatee,Sun, Ying,Liu, Jinqian,Luo, Jian,Zhang, Jane,Wong, Simon,Zhuang, Run,Guo, Qi,Li, Frank,Medina, Julio C.,Swaminath, Gayathri,Lin, Daniel C.-H.,Houze, Jonathan B.
, p. 726 - 730 (2012/10/30)
GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels. A potent, orally bioavailable small molecule GPR40 agonist
PYRROLIDINE GPR40 MODULATORS
-
Page/Page column 48, (2011/04/24)
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS
-
Page/Page column 105; 143, (2009/10/22)
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.